Table 3.

Adjusted clinical outcomes by degree of HLA-A, -B, -C and –DRB1 mismatch

	Number Events/Evaluable	Hazard ratio (95% confidence interval)	P-value
				Mortality*
HLA matched	44/234	1·00
1 allele mismatch	63/266	1·18 (0·80 – 1·72)	0·388
2 allele mismatch	88/303	1·55 (1·08 – 2·21)	0·018
3 allele mismatch	105/261	2·04 (1·44 – 2·89)	0·0001
≥4 allele mismatch	69/135	3·15 (2·16 – 4·58)	<0·0001
Graft failure†
HLA matched	39/233	1·00
1 allele mismatch	59/264	1·34 (0·90 – 1·98)	0·149
2 allele mismatch	72/302	1·50 (1·02 – 2·20)	0·037
3 allele mismatch	78/260	1·86 (1·27 – 2·73)	0·001
≥4 allele mismatch	35/135	1·62 (1·02 – 2·57)	0·041
Grade II-IV acute GVHD¶
HLA matched	52/228	1·00
1 allele mismatch	68/249	1·24 (0·87 – 1·78)	0·235
2 allele mismatch	85/291	1·36 (0·97 – 1·92)	0·077
3 allele mismatch	81/249	1·55 (1·09 – 2·20)	0·014
≥4 allele mismatch	47/130	1·72 (1·17 – 2·53)	0·006
Chronic GVHD§
HLA matched	51/228	1·00
1 allele mismatch	52/252	0·92 (0·63 – 1·34)	0·659
2 allele mismatch	68/296	1·06 (0·74 – 1·52)	0·757
3 allele mismatch	57/253	1·00 (0·69 – 1·47)	0·982
≥4 allele mismatch	33/133	1·15 (0·74 – 1·77)	0·539

Abbreviations: GVHD = graft versus host disease

^*Mortality risks for degree of HLA mismatch were adjusted for recipient cytomegalovirus serostatus, transplant conditioning regimen intensity, total nucleated cell dose of the cord blood unit and transplant period

^†Graft failure risks for degree of HLA mismatch were adjusted for transplant conditioning regimen intensity

^¶Model adjusted for transplant period and stratified by transplant conditioning regimen intensity and GVHD prophylaxis

^§Chronic GVHD risks were adjusted for GVHD prophylaxis